We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ONPPF market cap is 23.97M. The company's latest EPS is SEK -2.7544 and P/E is -0.09.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Revenue | 0 | 0 | 118.3M | 8.36M | 35.22M |
| Operating Income | -739.39M | -1.59B | -1.42B | -349.35M | -253.45M |
| Net Income | -740.71M | -1.59B | -1.43B | -337.95M | -249.11M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Assets | 993.49M | 946.76M | 439.38M | 385.32M | 238.38M |
| Total Liabilities | 196.48M | 369.86M | 228.51M | 91.03M | 181.6M |
| Total Equity | 797.01M | 576.9M | 210.87M | 294.29M | 56.78M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Operating | -690.57M | -1.3B | -1.52B | -420.51M | -279.49M |
| Investing | -2.63M | -20.13M | -339k | -2.51M | -116k |
| Financing | 1.24B | 1.32B | 1.03B | 392.4M | 108.61M |
| Market Cap | 23.97M |
| Price to Earnings Ratio | -0.09 |
| Price to Sales Ratio | 0.67 |
| Price to Cash Ratio | 0.14 |
| Price to Book Ratio | 0.41 |
| Dividend Yield | - |
| Shares Outstanding | 90.44M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 200 |
| 52 Week Change | -55.83% |
| 52 Week High | 0.60 |
| 52 Week Low | 0.265 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Oncopeptides AB (CE) |
| Address |
vastra tradgardsgatan 15 stockholm SE-111 53 |
| Website | https://www.oncopeptides.se |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
